Europe — EMA
Palonosetron Kalceks
Palonosetron, the active ingredient in Palonosetron Kalceks, is a 5‑HT3 receptor antagonist presented as a strength/form for intravenous use.
Request sourcing
What is Palonosetron?
Palonosetron, the active ingredient in Palonosetron Kalceks, is a 5‑HT3 receptor antagonist presented as a strength/form for intravenous use. It treats and prevents chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
GNH USA supplies Palonosetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Palonosetron used for?
Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting related to chemotherapy and surgery.
- Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting prevention of acute and delayed episodes. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea after general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps mitigate the nausea associated with certain radiation treatments.
